

DAHNO the catalyst to change Changing 21st century practice in Head and Neck Cancer

Richard Wight
On behalf DAHNO Project Team







5 current audits:-

- lung (LUCADA)
- head and neck (DAHNO)
- bowel
- mastectomy and breast reconstruction
- oesophago-gastric



What is DAHNO?




- <u>Da</u>ta for <u>h</u>ead and <u>n</u>eck <u>o</u>ncology
- National comparative audit in head and neck cancer in England and Wales
- Evolved as a partnership between BAHNO (British Association of Head and Neck Oncologists) and Information Centre (previously NHSIA) from 2003
- Phase 1 focus:-
 - "Delivery of appropriate primary treatment (including adjuvant therapy) in management of head and neck cancer affecting the larynx and oral cavity by a multi-professional team, and delivery of care to agreed standards"
- More than just a data base- it's a multi-professional approach to evaluating the standard of care we currently have and providing a catalyst to where we would like it to always be



Head and Neck Clinical Reference Group







Achievements of DAHNO 1



Patient benefit

- Active involvement of patient groups in working of project
- 3 annual reports with summary report in public domain
- Each trust receiving a focused feedback report to stimulate change to key leaders
- Action planning tool to assist local response

- Improvement in rate of discussion at MDT
- Improvement in recording of T and N staging prior to treatment decision








Professional


- The facilitation of standards with BAHNO
- Feedback to stimulate local change
- Viable expert team approach to converting data to information "setting the focus of the annual report"
- Improvement in rate of discussion at MDT
- Significant improvement in recording of T and N staging prior to treatment decision











CASE ASCERTAINMENT

67% of estimate overall

- DATA QUALITY
- Significant improvement
- CASES WITH T&N RECORDED

Up to 80%







Achievements of DAHNO 3


Professional


- Introduction of routine use of comorbidity calculation in the process of treatment consideration (ACE-27)
- Professional buy in across a variety of organisations/bodies
- Reproducible sound accepted methodology and standardisation
- Unified data set



The Information Centre

DAHNO 3RD ANNUAL REPORT





- ComorbiditySteady rise
- Performance status45% of registrations
- Cases discussed at MDT

74% discussed 6% not discussed 20% not recorded



Reporting at Trust and Network level to promote change in third annual report:-



TRUST

- Participation
- Number new larynx and oral cavity cancer primaries
- Percentage of those cases submitted with T and N category recorded
- Interval from biopsy to reporting
- Percentage of cases discussed at MDT
- Interval from diagnosis to MDT
- Interval from diagnosis to first definitive treatment (radiotherapy and surgery).

NETWORK

- Estimate number of cases
- Ratio of high to low stage disease
- Pre treatment and post resective pathology recorded
- Proportion of registrations (larynx/oral cavity) by quintile of deprivation







LUNG

- Participation
- Data quality
- MDT discussion
- Histological confirmation rate
- Any anti cancer treatment
 including treatment type
- Surgical resection rate
- Chemo rate for small cell

BOWEL

- Participation
- MDT discussion
- Specialist Nurse intervention
- Elective surgical patients receiving pre-op CT
- Pre op MRI Scanning
- Circumferential margin
- Pre-op radiotherapy
- Emergency Cases





INTERVAL FROM DIAGNOSIS TO FIRST DEFINITIVE TREATMENT IN LARYNX CANCER

Treatment	Trust	Treatment intent	Nos of cases	Min nos of days	Max nos of days	Median nos of days
RADIOTHERAPY	ALL	CURATIVE	225	14	107	46.5
	A	CURATIVE	21	16	107	36
	В	CURATIVE	22	27	68	46.5
	С	CURATIVE	18	31	77	53.5



Evolving benefits of DAHNO



- For Patients provide information to both patients and patient advocates to facilitate informed patient choice.
- For National monitoring bodies seeking assurance on quality of care delivered.
- For Commissioners of Services to be assured of the timeliness, quality and performance of local provision



Evolving benefits of DAHNO



- For Clinicians and Clinical Teams baseline measurement and comparators to promote improving clinical practice at a local level. Evidence gained to meet professional appraisal requirements.
- For Clinicians and Clinical Teams the evolution of a <u>high quality clinical database</u> to answer study questions
- For Provider Organisations provides focus to specific areas requiring improvement.
 Benchmarking local services against peer to drive up the quality of service provision.



Recommendations from 3rd Annual Report –via action planning tool



- Ensure Networks reflect on where variation in access occurs from trust identifiable data and examine underpinning pathways
- Meet patient expectations that all care discussions are being made at a MDT, and head and neck cancer teams provide assurance of this
- Ensure tumour staging (TNM) is confirmed and accurately recorded prior to care planning and following surgical procedures.
 This will enable true stage comparison of outcomes.










Extended anatomic areas

- Nasopharynx
- Oropharynx
- Hypopharynx
- Major Salivary Glands
- Extended range of pathologies

Multi-professional practice

- Clinical nurse specialist
- Dietetic
- Speech and language
 - Swallowing
 - Surgical Voice Restoration
- 4th report will include casemix adjustment









- WebDAHNO
- Can get relevant supporting documents and contacts at :
 - www.ic.nhs.uk
 - Select link NCASP
 - Then Select cancer





Acknowledge

- Valuable continuing partnership with NCASP, IC and UKACR
- Contribution expert panels
- Data management and access group
- Head and Neck Clinical Reference Group
- Cancer Registries in analysis support
- All individuals, trusts and Networks who contributed so far







